These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11023327)

  • 1. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.
    Simpson WG; Twomey P
    BMJ; 2000 Sep; 321(7261):637; author reply 638. PubMed ID: 11023327
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal age for starting lipid lowering treatment. It is more efficient to screen and treat elderly people.
    Marshall T
    BMJ; 2000 Sep; 321(7261):637; author reply 638. PubMed ID: 11023328
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.
    Jackson PR; Wallis EJ; Ramsay LE
    BMJ; 2000 Sep; 321(7261):637-8. PubMed ID: 11023329
    [No Abstract]   [Full Text] [Related]  

  • 4. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
    Mosca LJ
    Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
    Grundy SM
    Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reduction of coronary events: what are the possible mechanisms?].
    Badimón L; Pueyo Palazón C; Varela Villén O; Viñals Izquierdo M
    Rev Esp Cardiol; 1995; 48 Suppl 2():18-22. PubMed ID: 7569271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of risk factors in patients with coronary heart disease after in-patient rehabilitation].
    Küpper-Nybelen J; Rothenbacher D; Hahmann H; Wüsten B; Brenner H
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1525-30. PubMed ID: 12854061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D; Davis R
    Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Disordered lipid metabolism--current diagnostics].
    Schwandt P
    MMW Fortschr Med; 2003 Mar; 145(13):26-7. PubMed ID: 15101528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.